Andrej Lyshchik, M.D., PH.D
NPI: 1356534895
Total Payments
$593,700
2024 Payments
$43,475
Companies
7
Transactions
153
Medicare Patients
5,974
Medicare Billing
$361,785
Payment Breakdown by Category
Research$323,378 (54.5%)
Consulting$190,580 (32.1%)
Other$60,642 (10.2%)
Travel$17,977 (3.0%)
Food & Beverage$1,123 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $323,378 | 19 | 54.5% |
| Consulting Fee | $190,580 | 54 | 32.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,642 | 35 | 10.2% |
| Travel and Lodging | $17,977 | 32 | 3.0% |
| Food and Beverage | $1,123 | 13 | 0.2% |
Payments by Type
Research
$323,378
19 transactions
General
$270,322
134 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $320,510 | 18 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $181,430 | 50 | $0 (2021) |
| GE HEALTHCARE | $81,575 | 77 | $0 (2024) |
| BRACCO DIAGNOSTICS INC. | $5,421 | 3 | $0 (2022) |
| Lantheus Medical Imaging, Inc. | $4,556 | 2 | $0 (2023) |
| Siemens Medical Solutions USA, Inc. | $182.89 | 2 | $0 (2021) |
| Medtronic USA, Inc. | $24.36 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,475 | 7 | E.R. Squibb & Sons, L.L.C. ($39,475) |
| 2023 | $171,816 | 11 | E.R. Squibb & Sons, L.L.C. ($161,635) |
| 2022 | $57,300 | 9 | E.R. Squibb & Sons, L.L.C. ($52,150) |
| 2021 | $207,591 | 40 | Merck Sharp & Dohme Corporation ($134,490) |
| 2020 | $50,670 | 18 | Merck Sharp & Dohme Corporation ($45,470) |
| 2019 | $31,522 | 21 | GE HEALTHCARE ($30,052) |
| 2018 | $31,029 | 45 | GE Healthcare ($30,851) |
| 2017 | $296.94 | 2 | GE HEALTHCARE ($296.94) |
All Payment Transactions
153 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/22/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $75.00 | Research |
| Study: A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $21,435.00 | Research |
| Study: Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $9,075.00 | Research |
| Study: Ph III Nivo SC in previosly treated adv or met clear RCC with Biocomparability Study - A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metas • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $5,530.00 | Research |
| Study: Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par • Category: Oncology | ||||||
| 01/04/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $3,360.00 | Research |
| Study: Fuc-GM1 + nivo/chemo vs nivo/chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | ||||||
| 01/03/2024 | GE HEALTHCARE | LOGIQ (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Ultrasound | ||||||
| 01/03/2024 | GE HEALTHCARE | LOGIQ (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Ultrasound | ||||||
| 10/26/2023 | LANTHEUS MEDICAL IMAGING, INC. | DEFINITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,404.00 | General |
| Category: CONTRAST AGENT | ||||||
| 09/05/2023 | Lantheus Medical Imaging, Inc. | DEFINITY (Drug) | Food and Beverage | In-kind items and services | $152.27 | General |
| Category: CONTRAST AGENT | ||||||
| 06/07/2023 | GE HEALTHCARE | Versana (Device) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Ultrasound | ||||||
| 06/07/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $75.00 | Research |
| Study: Phase III Adjuvant Bladder (nivo mono) • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $72,855.00 | Research |
| Study: Ph III Nivo SC in previosly treated adv or met clear RCC - A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell • Category: Oncology | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $52,695.00 | Research |
| Study: Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $18,205.00 | Research |
| Study: Fuc-GM1 + nivo/chemo vs nivo/chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $17,730.00 | Research |
| Study: Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par • Category: Oncology | ||||||
| 01/05/2023 | GE HEALTHCARE | LOGIQ (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Ultrasound | ||||||
| 01/05/2023 | GE HEALTHCARE | LOGIQ (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Ultrasound | ||||||
| 01/05/2023 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $75.00 | Research |
| Study: Ph2 Randomized Single Dbl Blind 1L NSCLC (TIGIT + Nivo/IPI vs Nivo/Ipi) | ||||||
| 07/20/2022 | GE HealthCare | LOGIQ (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Ultrasound | ||||||
| 06/08/2022 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $22,845.00 | Research |
| Study: Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo | ||||||
| 04/01/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $10,515.00 | Research |
| Study: Ph III Nivo SC in previosly treated adv or met clear RCC - A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell • Category: Oncology | ||||||
| 03/22/2022 | BRACCO DIAGNOSTICS INC. | Lumason (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Diagnostic Imaging | ||||||
| 01/12/2022 | GE HealthCare | LOGIQ (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Ultrasound | ||||||
| 01/12/2022 | GE HealthCare | LOGIQ (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Ultrasound | ||||||
| 01/06/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | — | Cash or cash equivalent | $14,505.00 | Research |
| Study: Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph III Nivo SC in previosly treated adv or met clear RCC - A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell | E.R. Squibb & Sons, L.L.C. | $83,370 | 2 |
| Phase III Adjuvant Bladder nivo mono | E.R. Squibb & Sons, L.L.C. | $63,070 | 2 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) | E.R. Squibb & Sons, L.L.C. | $52,695 | 1 |
| Phase III Nivo+Ipi vs Placebo in Adjuvant RCC (Part B FA) - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Par | E.R. Squibb & Sons, L.L.C. | $23,260 | 2 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo | E.R. Squibb & Sons, L.L.C. | $22,845 | 1 |
| Fuc-GM1 + nivo/chemo vs nivo/chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | E.R. Squibb & Sons, L.L.C. | $21,565 | 2 |
| Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) | E.R. Squibb & Sons, L.L.C. | $21,435 | 1 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC - A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec | E.R. Squibb & Sons, L.L.C. | $14,505 | 1 |
| Ph III Nivo SC in previosly treated adv or met clear RCC with Biocomparability Study - A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metas | E.R. Squibb & Sons, L.L.C. | $9,075 | 1 |
| Phase III Nivo Ipi vs Placebo in Adjuvant RCC | E.R. Squibb & Sons, L.L.C. | $4,680 | 1 |
| Fuc-GM1 nivo chemo vs nivo chemo in 1L IO Naive SCLC - A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer | E.R. Squibb & Sons, L.L.C. | $3,785 | 1 |
| LYSHCHIK_CONTRAST ENHANCED ULTRASOUND EVALUATION OF FOCAL LIVER LESIONS IN PATIENTS WITH CIRRHOSIS OR OTHER RISK FACTORS FOR DEVELOPING HCC | BRACCO DIAGNOSTICS INC. | $2,868 | 1 |
| A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| Ph2 Randomized Single Dbl Blind 1L NSCLC (TIGIT + Nivo/IPI vs Nivo/Ipi) | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
| Phase III Adjuvant Bladder (nivo mono) | E.R. Squibb & Sons, L.L.C. | $75.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 1,610 | 12,791 | $1.2M | $94,215 |
| 2022 | 30 | 1,552 | 12,916 | $1.0M | $93,127 |
| 2021 | 30 | 1,350 | 6,035 | $617,429 | $78,581 |
| 2020 | 31 | 1,462 | 6,382 | $830,923 | $95,861 |
Total Patients
5,974
Total Services
38,124
Medicare Billing
$361,785
Procedure Codes
142
All Medicare Procedures & Services
142 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 71 | 71 | $217,521 | $17,914 | 8.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 136 | 137 | $63,705 | $8,844 | 13.9% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 24 | 24 | $84,546 | $6,827 | 8.1% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 62 | 63 | $160,246 | $5,989 | 3.7% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 38 | 40 | $110,612 | $5,788 | 5.2% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 47 | 50 | $107,923 | $5,264 | 4.9% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 77 | 77 | $28,875 | $5,080 | 17.6% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Facility | 2023 | 155 | 157 | $40,820 | $4,047 | 9.9% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 45 | 45 | $71,592 | $3,568 | 5.0% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2023 | 103 | 108 | $20,520 | $2,917 | 14.2% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 32 | 32 | $23,019 | $2,778 | 12.1% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 38 | 39 | $23,985 | $2,590 | 10.8% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 59 | 59 | $17,700 | $2,410 | 13.6% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 57 | 58 | $15,660 | $2,190 | 14.0% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2023 | 78 | 82 | $12,710 | $1,703 | 13.4% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 18 | 18 | $30,492 | $1,573 | 5.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Facility | 2023 | 48 | 48 | $17,280 | $1,410 | 8.2% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 115 | 11,265 | $25,832 | $1,371 | 5.3% |
| 74174 | Ct scan of blood vessels of abdomen and pelvis with contrast | Facility | 2023 | 15 | 16 | $11,200 | $1,367 | 12.2% |
| 76705 | Limited ultrasound scan of abdomen | Office | 2023 | 15 | 16 | $16,670 | $1,142 | 6.8% |
| 76700 | Complete ultrasound scan of abdomen | Facility | 2023 | 37 | 37 | $7,400 | $1,100 | 14.9% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Facility | 2023 | 26 | 27 | $6,615 | $1,091 | 16.5% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Facility | 2023 | 15 | 15 | $8,100 | $1,013 | 12.5% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Facility | 2023 | 52 | 53 | $5,300 | $907.92 | 17.1% |
| 76882 | Limited ultrasound scan of joint or other extremity structure except blood vessels | Facility | 2023 | 26 | 29 | $2,610 | $759.08 | 29.1% |
About Andrej Lyshchik, M.D., PH.D
Andrej Lyshchik, M.D., PH.D is a Vascular & Interventional Radiology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356534895.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Andrej Lyshchik, M.D., PH.D has received a total of $593,700 in payments from pharmaceutical and medical device companies, with $43,475 received in 2024. These payments were reported across 153 transactions from 7 companies. The most common payment nature is "" ($323,378).
As a Medicare-enrolled provider, Lyshchik has provided services to 5,974 Medicare beneficiaries, totaling 38,124 services with total Medicare billing of $361,785. Data is available for 4 years (2020–2023), covering 142 distinct procedure/service records.
Ad
Practice Information
- Specialty Vascular & Interventional Radiology
- Other Specialties Diagnostic Radiology, Diagnostic Radiology
- Location Philadelphia, PA
- Active Since 08/18/2007
- Last Updated 10/18/2016
- Taxonomy Code 2085R0204X
- Entity Type Individual
- NPI Number 1356534895
Products in Payments
- OPDIVO (Biological) $198,110
- LENVIMA (Drug) $138,565
- KEYTRUDA (Biological) $31,800
- WELIREG (Drug) $11,065
- LOGIQ (Device) $10,750
- Lumason (Drug) $5,268
- DEFINITY (Drug) $4,556
- Versana (Device) $1,625
- ACUSON Sequoia Diagnostic Ultrasound System (Device) $182.89
- CEUS (Drug) $153.46
- OSTEOCOOL RF ABLATION (Device) $24.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Vascular & Interventional Radiology Doctors in Philadelphia
Scott Trerotola, Md, MD
Vascular & Interventional Radiology — Payments: $1.7M
Vascular & Interventional Radiology $1.7M
Timothy Clark, Md, MD
Vascular & Interventional Radiology — Payments: $777,227
Vascular & Interventional Radiology $777,227
Dr. Abhishek Kumar, M.d, M.D
Vascular & Interventional Radiology — Payments: $281,087
Vascular & Interventional Radiology $281,087
Jason Hoffmann
Vascular & Interventional Radiology — Payments: $193,068
Vascular & Interventional Radiology $193,068
Michael Soulen, Md, MD
Vascular & Interventional Radiology — Payments: $115,695
Vascular & Interventional Radiology $115,695
Noor Ahmad, Md, MD
Vascular & Interventional Radiology — Payments: $88,599
Vascular & Interventional Radiology $88,599